2022 Q3 Form 10-Q Financial Statement
#000155837022013500 Filed on August 12, 2022
Income Statement
Concept | 2022 Q3 | 2022 Q2 | 2022 Q1 |
---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $2.533M | $2.237M | $1.955M |
YoY Change | 22.37% | 16.88% | -10.73% |
% of Gross Profit | |||
Research & Development | $571.0K | $982.0K | $920.0K |
YoY Change | -59.04% | -51.19% | -19.51% |
% of Gross Profit | |||
Depreciation & Amortization | $2.000K | $5.000K | $12.00K |
YoY Change | -83.33% | -58.33% | 0.0% |
% of Gross Profit | |||
Operating Expenses | $571.0K | $982.0K | $920.0K |
YoY Change | -59.04% | -51.19% | -19.51% |
Operating Profit | -$3.104M | -$3.219M | -$2.875M |
YoY Change | -10.39% | -18.01% | -13.66% |
Interest Expense | $0.00 | $0.00 | $0.00 |
YoY Change | -100.0% | -100.0% | -100.0% |
% of Operating Profit | |||
Other Income/Expense, Net | -$9.000K | -$84.00K | |
YoY Change | |||
Pretax Income | -$3.113M | -$3.303M | -$2.875M |
YoY Change | -10.05% | -15.76% | -13.51% |
Income Tax | $0.00 | $0.00 | $0.00 |
% Of Pretax Income | |||
Net Earnings | -$3.100M | -$3.300M | -$2.875M |
YoY Change | -10.43% | -15.38% | -13.51% |
Net Earnings / Revenue | |||
Basic Earnings Per Share | -$3.50 | -$0.12 | -$0.11 |
Diluted Earnings Per Share | -$3.50 | -$0.12 | -$0.11 |
COMMON SHARES | |||
Basic Shares Outstanding | 26.66M | 26.66M | 26.66M |
Diluted Shares Outstanding | 888.7K | 26.66M | 26.66M |
Balance Sheet
Concept | 2022 Q3 | 2022 Q2 | 2022 Q1 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $6.356M | $8.849M | $11.56M |
YoY Change | -8.99% | -6.98% | -11.37% |
Cash & Equivalents | $6.400M | $8.800M | $11.60M |
Short-Term Investments | |||
Other Short-Term Assets | $1.198M | $1.228M | $1.707M |
YoY Change | 2395.83% | 639.76% | 98.49% |
Inventory | |||
Prepaid Expenses | $859.0K | $1.228M | $1.707M |
Receivables | |||
Other Receivables | |||
Total Short-Term Assets | $7.554M | $10.08M | $13.26M |
YoY Change | -3.7% | -3.74% | -4.51% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $3.000K | $5.000K | $98.00K |
YoY Change | -97.54% | -96.27% | -63.7% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | |||
YoY Change | |||
Total Long-Term Assets | $3.000K | $5.000K | $197.0K |
YoY Change | -98.71% | -98.01% | -27.04% |
TOTAL ASSETS | |||
Total Short-Term Assets | $7.554M | $10.08M | $13.26M |
Total Long-Term Assets | $3.000K | $5.000K | $197.0K |
Total Assets | $7.557M | $10.08M | $13.46M |
YoY Change | -6.44% | -5.94% | -4.94% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $1.075M | $664.0K | $776.0K |
YoY Change | 12.8% | 91.35% | 65.11% |
Accrued Expenses | $544.0K | $585.0K | $693.0K |
YoY Change | -41.0% | -27.87% | 44.38% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $1.619M | $1.249M | $1.496M |
YoY Change | -14.83% | 5.58% | 59.15% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | $0.00 | $0.00 | $37.00K |
YoY Change | -100.0% | -100.0% | -47.14% |
Total Long-Term Liabilities | $0.00 | $0.00 | $37.00K |
YoY Change | -100.0% | -100.0% | -47.14% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $1.619M | $1.249M | $1.496M |
Total Long-Term Liabilities | $0.00 | $0.00 | $37.00K |
Total Liabilities | $1.619M | $1.249M | $1.533M |
YoY Change | -17.06% | 0.64% | 51.78% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$91.10M | -$88.00M | -$84.70M |
YoY Change | 17.93% | 19.24% | |
Common Stock | $1.000K | $27.00K | $27.00K |
YoY Change | -95.45% | 22.73% | |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $5.938M | $8.833M | $11.93M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $7.557M | $10.08M | $13.46M |
YoY Change | -6.44% | -5.94% | -4.94% |
Cashflow Statement
Concept | 2022 Q3 | 2022 Q2 | 2022 Q1 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$3.100M | -$3.300M | -$2.875M |
YoY Change | -10.43% | -15.38% | -13.51% |
Depreciation, Depletion And Amortization | $2.000K | $5.000K | $12.00K |
YoY Change | -83.33% | -58.33% | 0.0% |
Cash From Operating Activities | -$2.359M | -$2.717M | -$4.829M |
YoY Change | -5.9% | -24.28% | -21.36% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $0.00 | ||
YoY Change | |||
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $0.00 | $8.000K | $0.00 |
YoY Change | |||
Cash From Investing Activities | $0.00 | $8.000K | $0.00 |
YoY Change | -366.67% | ||
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | -134.0K | 0.000 | 0.000 |
YoY Change | 458.33% | -100.0% | -100.0% |
NET CHANGE | |||
Cash From Operating Activities | -2.359M | -2.717M | -4.829M |
Cash From Investing Activities | 0.000 | 8.000K | 0.000 |
Cash From Financing Activities | -134.0K | 0.000 | 0.000 |
Net Change In Cash | -2.493M | -2.709M | -4.829M |
YoY Change | -1.5% | -22.97% | -263.64% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$2.359M | -$2.717M | -$4.829M |
Capital Expenditures | $0.00 | ||
Free Cash Flow | -$2.359M | ||
YoY Change | -5.9% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2022Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2021Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2022Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
CY2021Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
CY2022Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.12 | |
CY2021Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.18 | |
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.23 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.33 | ||
CY2022Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
26661771 | |
CY2021Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
22000074 | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
26661771 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
21909464 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-7256000 | ||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001638287 | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2022 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
CY2022Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2021Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2022Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
26661771 | |
CY2021Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
26661771 | |
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2022-06-30 | ||
dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
dei |
Entity File Number
EntityFileNumber
|
001-37809 | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
NeuroBo Pharmaceuticals, Inc. | ||
dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | ||
dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
47-2389984 | ||
dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
200 Berkeley Street, Office 19th Floor | ||
dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Boston | ||
dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
MA | ||
dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
02116 | ||
dei |
City Area Code
CityAreaCode
|
857 | ||
dei |
Local Phone Number
LocalPhoneNumber
|
702-9600 | ||
dei |
Security12b Title
Security12bTitle
|
Common stock | ||
dei |
Trading Symbol
TradingSymbol
|
NRBO | ||
dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | ||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
dei |
Entity Shell Company
EntityShellCompany
|
false | ||
CY2022Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
26661771 | |
CY2022Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
8849000 | |
CY2021Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
16387000 | |
CY2022Q2 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
1228000 | |
CY2021Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
197000 | |
CY2022Q2 | us-gaap |
Assets Current
AssetsCurrent
|
10077000 | |
CY2021Q4 | us-gaap |
Assets Current
AssetsCurrent
|
16584000 | |
CY2021Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
105000 | |
CY2022Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
5000 | |
CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
110000 | |
CY2022Q2 | us-gaap |
Assets
Assets
|
10082000 | |
CY2021Q4 | us-gaap |
Assets
Assets
|
16799000 | |
CY2022Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
664000 | |
CY2021Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
830000 | |
CY2022Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
585000 | |
CY2021Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1301000 | |
CY2021Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
26000 | |
CY2022Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1249000 | |
CY2021Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
2157000 | |
CY2021Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
45000 | |
CY2022Q2 | us-gaap |
Liabilities
Liabilities
|
1249000 | |
CY2021Q4 | us-gaap |
Liabilities
Liabilities
|
2202000 | |
CY2022Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2021Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2022Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
CY2021Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
CY2022Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2021Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2022Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2021Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2022Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
CY2021Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
CY2022Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
26661771 | |
CY2021Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
26661771 | |
CY2022Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
27000 | |
CY2021Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
27000 | |
CY2022Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
96812000 | |
CY2021Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
96394000 | |
CY2021Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
4000 | |
CY2022Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-88006000 | |
CY2021Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-81828000 | |
CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8833000 | |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
14597000 | |
CY2022Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
10082000 | |
CY2021Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
16799000 | |
CY2022Q2 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
982000 | |
CY2021Q2 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
2012000 | |
us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
1902000 | ||
us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
3155000 | ||
CY2022Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2237000 | |
CY2021Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1914000 | |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4192000 | ||
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4101000 | ||
CY2022Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
3219000 | |
CY2021Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
3926000 | |
us-gaap |
Costs And Expenses
CostsAndExpenses
|
6094000 | ||
us-gaap |
Costs And Expenses
CostsAndExpenses
|
7256000 | ||
CY2022Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3219000 | |
CY2021Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3926000 | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-6094000 | ||
CY2021Q2 | us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
5000 | |
us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
11000 | ||
CY2022Q2 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
84000 | |
us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
84000 | ||
CY2022Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-3303000 | |
CY2021Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-3921000 | |
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-6178000 | ||
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-7245000 | ||
CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3303000 | |
CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3921000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-6178000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-7245000 | ||
CY2022Q2 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-3000 | |
CY2021Q2 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-4000 | |
us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-4000 | ||
us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-11000 | ||
CY2022Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-3306000 | |
CY2021Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-3925000 | |
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-6182000 | ||
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-7256000 | ||
CY2022Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.12 | |
CY2021Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.18 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.23 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.33 | ||
CY2022Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
26661771 | |
CY2021Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
22000074 | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
26661771 | ||
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
21909464 | ||
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
7203000 | |
CY2021Q1 | nrbo |
Stock And Warrants Issued During Period Value
StockAndWarrantsIssuedDuringPeriodValue
|
10000000 | |
CY2021Q1 | nrbo |
Adjustments To Additional Paid In Capital Transaction Costs In Connection With Equity Financing
AdjustmentsToAdditionalPaidInCapitalTransactionCostsInConnectionWithEquityFinancing
|
908000 | |
CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
187000 | |
CY2021Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
|
-7000 | |
CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3324000 | |
CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
13151000 | |
CY2021Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
180000 | |
CY2021Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
72000 | |
CY2021Q2 | us-gaap |
Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
|
-4000 | |
CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3921000 | |
CY2021Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
9478000 | |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
14597000 | |
CY2022Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
207000 | |
CY2022Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
|
-1000 | |
CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2875000 | |
CY2022Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
11928000 | |
CY2022Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
211000 | |
CY2022Q2 | us-gaap |
Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
|
-3000 | |
CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3303000 | |
CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8833000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-6178000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-7245000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
418000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
367000 | ||
nrbo |
Increase Decrease In Non Cash Lease Expense
IncreaseDecreaseInNonCashLeaseExpense
|
8000 | ||
CY2022Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
5000 | |
nrbo |
Increase Decrease In Non Cash Lease Expense
IncreaseDecreaseInNonCashLeaseExpense
|
12000 | ||
us-gaap |
Depreciation
Depreciation
|
17000 | ||
us-gaap |
Depreciation
Depreciation
|
24000 | ||
us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-75000 | ||
nrbo |
Increase Decrease In Prepaid Expenses And Deposits
IncreaseDecreaseInPrepaidExpensesAndDeposits
|
997000 | ||
nrbo |
Increase Decrease In Prepaid Expenses And Deposits
IncreaseDecreaseInPrepaidExpensesAndDeposits
|
361000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-165000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-2228000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-724000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-297000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-7546000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-9728000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
3000 | ||
us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
8000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
8000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-3000 | ||
us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
10000000 | ||
us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
908000 | ||
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
72000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
9164000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-7538000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-567000 | ||
us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-9000 | ||
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
16387000 | |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
10089000 | |
CY2022Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
8849000 | |
CY2021Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
9513000 | |
nrbo |
Modification Of Right Of Use Asset And Associated Lease Liability
ModificationOfRightOfUseAssetAndAssociatedLeaseLiability
|
62000 | ||
CY2022Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
8800000 | |
CY2022Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-88000000.0 | |
CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3300000 | |
CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3900000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-6200000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-7200000 | ||
us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company's condensed consolidated financial statements relate to accrued expenses and the fair value of stock-based compensation and warrant issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgements about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p> | ||
CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
110000 | |
us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-75000 | ||
CY2022Q2 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
30000 | |
CY2021Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
221000 | |
CY2022Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
25000 | |
CY2021Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
111000 | |
CY2022Q2 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-75000 | |
CY2022Q2 | nrbo |
Accrued Other Research And Development Expenses
AccruedOtherResearchAndDevelopmentExpenses
|
468000 | |
CY2021Q4 | nrbo |
Accrued Other Research And Development Expenses
AccruedOtherResearchAndDevelopmentExpenses
|
854000 | |
CY2022Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
11000 | |
CY2021Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
376000 | |
CY2022Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
70000 | |
CY2021Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
59000 | |
CY2022Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
36000 | |
CY2021Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
12000 | |
CY2022Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
585000 | |
CY2021Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1301000 | |
CY2022Q2 | nrbo |
Percentage Of Royalty Payments
PercentageOfRoyaltyPayments
|
0.025 | |
CY2022Q2 | nrbo |
Royalty Payment Accrued
RoyaltyPaymentAccrued
|
0 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
0.807 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
0.852 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0172 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0308 | ||
CY2022Q2 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
6846633 | |
CY2021Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
6885748 | |
CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
974999 | |
CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
3.99 | |
CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P9Y3M18D | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
180000 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
0.59 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
60000 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
6.04 | ||
CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1094999 | |
CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
3.32 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P9Y | ||
CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
1000 | |
CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
1094999 | |
CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
3.32 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P9Y | ||
CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
1000 | |
CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
223887 | |
CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
7.95 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P7Y8M12D | ||
us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0 | ||
CY2021Q2 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0 | |
us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0 | ||
CY2022Q2 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0 | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | ||
CY2021Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | ||
CY2022Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 |